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Keratinocyte differentiation 
induces APOBEC3A, 3B, and 
mitochondrial DNA hypermutation
Kousho Wakae1, Tomoaki Nishiyama  2, Satoru Kondo3, Takashi Izuka4, Lusheng Que  1, 
Cong Chen1,5, Kina Kase3, Kouichi Kitamura  1, Md Mohiuddin1, Zhe Wang1,5,  
Md Monjurul Ahasan1,9, Mitsuhiro Nakamura4, Hiroshi Fujiwara4, Tomokazu Yoshizaki3, 
Kazuyoshi Hosomochi6, Atsushi Tajima  6, Tomomi Nakahara7, Tohru Kiyono  7 &  
Masamichi Muramatsu1,8
Mitochondrial DNA (mtDNA) mutations are found in many types of cancers and suspected to be 
involved in carcinogenesis, although the mechanism has not been elucidated. In this study, we 
report that consecutive C-to-T mutations (hypermutations), a unique feature of mutations induced 
by APOBECs, are found in mtDNA from cervical dysplasia and oropharyngeal cancers. In vitro, we 
found that APOBEC3A (A3A) and 3B (A3B) expression, as well as mtDNA hypermutation, were 
induced in a cervical dysplastic cell line W12 when cultured in a differentiating condition. The ectopic 
expression of A3A or A3B was sufficient to hypermutate mtDNA. Fractionation of W12 cell lysates and 
immunocytochemical analysis revealed that A3A and A3B could be contained in mitochondrion. These 
results suggest that mtDNA hypermutation is induced upon keratinocyte differentiation, and shed light 
on its molecular mechanism, which involves A3s. The possible involvement of mtDNA hypermutations 
in carcinogenesis is also discussed.
Associations have been found between mitochondrial DNA (mtDNA) mutations and cervical and oral squamous 
cell carcinoma1–5. This has been linked with the Warburg effect, a metabolic shift from oxidative phosphorylation 
to glycolysis in tumour cells6,7. Oxidative phosphorylation abundantly produces reactive oxygen species (ROS), 
and their proximity to mtDNA is believed to play important roles in the accumulation of mtDNA mutations. 
mtDNA mutations potentially result in dysfunction of the respiratory chain complex, increasing ROS levels, DNA 
oxidation, genomic instability, and tumourigenesis6,7. mtDNA mutations are associated with distant metastases in 
lung and colon cancers, and are experimentally shown to facilitate the growth and metastasis of cancer cells8–11. 
However, the exact mechanisms for how mtDNA mutations are induced and how they contribute to carcinogen-
esis remain to be elucidated. The majority of mtDNA mutations are believed to be created via DNA oxidization, 
especially guanine oxidization into 8-oxoguanine (8-oxoG), which results in G:C to T:A mutations12. However, 
mutations other than G-to-T are also often found4,13, suggesting that ROS are not the sole mutagen for mtDNA.
APOBEC proteins are a family of enzymes that convert cytosine into uracil in DNA and RNA. In humans, the 
APOBEC family is composed of 11 members, including AID and APOBEC1, 2, 3A, 3B, 3C, 3DE, 3F, 3G, 3H, and 
414–17. APOBEC3s (A3s) are counteracting factors against viruses such as HIV-1 and transposable elements14–17. 
As well as their established role as antiviral molecules, it has been proposed that they may be oncogenic by 
hypermutating host genomes. In vivo, consecutive C-to-T/G-to-A mutations, which share features with those 
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introduced by APOBECs, are found in multiple human tumours including bladder, cervical, lung, head, and 
neck, and breast cancers18,19. Also, APOBEC3A (A3A) expression is correlated with genomic integration of an 
oncogenic virus, Human Papillomavirus 16 (HPV16) in oropharyngeal cancer (OPC)20. In vitro, A3A mutates 
chromosomal genes TP53 and c-myc20,21, as well as causes DNA strand breaks22–24. Regarding the mitochondrial 
genome, Suspene et al. reported that overexpression of A3A in HeLa cells resulted in mtDNA hypermutation21. 
Although the ability of A3s to hypermutate mtDNA has been demonstrated, the pathophysiological context for 
this remains to be determined.
We hypothesized that A3s induce mtDNA mutation, contributing to carcinogenesis. In this study, we have 
attempted to clarify the molecular mechanism underlying how this may occur.
Results
Hypermutated mtDNA in cervical dysplasia and oropharyngeal cancer. It has been reported that 
mtDNA was mutated in many types of cancers, including cervical cancer (CC) and OPC13,25,26. We have previously 
Figure 1. mtDNA hypermutation in cervical dysplasia and oropharyngeal cancer. Total DNA samples were 
extracted from cervical intraepithelial neoplasia (CIN) 1/2 vaginal swabs, paraffin-embedded HPV16 CIN3, 
cervical cancer, and oropharyngeal cancer (OPC). (a) 3D-PCR analysis targeting COI was performed along 
with plasmids containing COI amplicons with the indicated number of C-to-T mutations as control reactions 
(n.c. indicates the no-mutation control, whereas 4× and 17× indicate 4 and 17 C-to-T mutations, respectively). 
The dotted lines indicate the lowest denaturing temperature, 84.9 °C, at which COI was amplified from n.c. 
The results for seven cervical dysplasia/cancer and ten OPC samples are shown representatively. (b,c) 3D-
PCR products amplified at denaturation temperatures of 84.5 °C or lower were sequenced and mapped to a 
reference sequence (GenBank accession number: NC_012920.1). The identified mutations are summarized in 
matrices (b) and the result of the 5′-dinucleotide context analysis is shown in (c) (*P < 0.05 and ***P < 0.005). 
(d,e) RT-qPCR (d) and immunohistochemical analysis (e) of A3B in OPCs. OPC samples were divided into 
two groups according to the lowest denaturing temperature at which COI was amplified (mtDNA mut low; 
>84.1 °C, high; <=84.1 °C). (e) A3B protein levels were indicated as expression scores, based on the frequency 
of immunoreactive cells.
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reported that A3s are abundantly expressed in the human cervix, OPCs, and cervical intraepithelial neoplasia 
(CIN) or OPC cell lines20,27,28. In addition, HPV16 E6 and E7 reportedly induce A3A and APOBEC3B(A3B) 
expression29,30. These findings led us to hypothesize that A3s hypermutate mtDNAs in HPV16-related dysplasia 
and cancer, and to analyse hypermutations in mtDNA with high sensitivity by using differential DNA denatur-
ation PCR (3D-PCR)21. Total DNAs from 10 cervical specimens (two CIN1, one CIN2, five CIN3, and two CC) 
were subjected to 3D-PCR targeting COI and ND2, along with the control plasmid DNA containing 0, 4, and 
17 C-to-T mutations for COI, and 0, 9, and 14 for ND2, respectively. For the COI control plasmids, the lowest 
temperatures of amplification were 84.9 °C, 84.1 °C, and 82.6 °C for 0, 4, and 17 C-to-T mutations, respectively 
(Fig. 1a). For the ND2 control plasmids, the lowest temperatures were 83.5 °C, 82.6 °C, and 81.9 °C for 0, 9, and 
14 C-to-T mutations, respectively (Supplementary Fig. S1a). These indicate that our 3D-PCR analysis was able to 
quantify mutation load per amplicon.
COI was amplified from 8 out of 10 samples at a denaturing temperature lower than 84.9 °C, the lowest at 
which COI is amplified from no-mutation control plasmids (Fig. 1a). Notably, it was amplified at a tempera-
ture as low as 82.6 °C for one of the CIN1 specimens (#1300). ND2 was also amplified from 3 out of 10 samples 
at temperature lower than 83.5 °C, the lowest at which ND2 is amplified from no-mutation control plasmids 
(Supplementary Fig. S1a). It could be amplified at temperatures of 81.9 °C, 82.2 °C, and 82.6 °C from specimens 
#1300, #2159, and KA-006, respectively. In addition, 33 OPC specimens were tested for COI 3D-PCR and it was 
found that COI could be amplified from 11 samples at denaturing temperature at 84.5 °C or less (Figs 1a and 
S2a). The PCR products amplified at denaturing temperatures lower than 84.9° (COI) or 83.5 °C (ND2) were 
collected from four samples for COI (#1300, KZU22, KZU33, and KZU45) and two for ND2 (#1300 and KA006), 
and sequenced. The result revealed accumulated G-to-A mutations, but no other types of mutation, a unique 
D-loop - ND1
number of C-to-T or G-to-A per read
0 to 3 4 5 6 7 8 10 22
plasmid 2423061 0 0 0 0 0 0 0
CIN1 #1300 2382107 8 8 4 2 0 1 0
CIN2 #2159 2121943 0 0 0 0 0 0 0
OPC KZU33 1303978 0 0 0 0 0 0 0
OPC KZU45 1150214 2 0 1 0 1 0 1
Table 1. Hypermutated mtDNA in CINs and OPCs (D-loop-ND1).
ND1 - ATP6
number of C-to-T or G-to-A per read
0 to 3 4 5 6 7 22
CIN1 #1300 2817768 4 1 0 2 0
CIN2 #2159 2443256 0 0 0 0 0
OPC KZU33 2015183 1 0 0 0 0
OPC KZU45 1729775 0 0 0 0 1
Table 2. Hypermutated mtDNA in CINs and OPCs (ND1-ATP6).
ATP6 - ND5
number of C-to-T or G-to-A per read
0 to 3 5 10 13
CIN1 #1300 2093340 1 0 0
CIN2 #2159 1774190 0 0 0
OPC KZU33 1298772 0 0 0
OPC KZU45 1234401 0 1 2
Table 3. Hypermutated mtDNA in CINs and OPCs (ATP6-ND5).
ND5 - tRNA-F
number of C-to-T or G-to-A per read
0 to 3 4 5 6 10 12
CIN1 #1300 2419905 8 4 4 1 1
CIN2 #2159 2175074 0 0 0 0 0
OPC KZU33 1358320 1 1 0 0 0
OPC KZU45 1209281 2 0 1 0 1
Table 4. Hypermutated mtDNA in CINs and OPCs (ND5-tRNA-F).
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feature of APOBEC-mediated hypermutation (Figs 1b and S1b). The presence of exclusive G-to-A mutations in 
these samples suggests that A3s target cytosine in the complementary strand. Dinucleotide preference analysis of 
C-to-T/G-to-A mutations revealed a bias toward TpC and CpC, over ApC or GpC (Figs 1c and S1c), consistent 
with the reported characteristics for A3s31–34. These results indicate that mtDNA is hypermutated in CIN and 
OPC samples.
Because HPV16 reportedly induces A3A and A3B29,30, the association between HPV16 infection and mtDNA 
hypermutation was examined. When the threshold was set at 84.5 °C (4 × p.c.), 33% of both HPV16 (+) and HPV 
(−) OPCs were positive for mtDNA hypermutation, suggesting no obvious association between infection and 
hypermutation (Supplementary Fig. S2b). With regards to the correlation between A3 expression and mtDNA 
hypermutation, we found that both mRNA and protein levels of A3B were significantly higher in specimens with 
mtDNA hypermutation than those without hypermutation (Fig. 1d and e). For other A3s, we could not find obvi-
ous correlation between their expression and the load of mtDNA mutations (Supplementary Fig. S3).
We further investigated whether chromosomal and HPV16 DNA hypermutations were associated with 
mtDNA hypermutation. We used 3D-PCR to target TP53, but we were unable to find any sign of hypermutation 
greater than four C-to-T plasmid controls (Supplementary Fig. S4a). For HPV16 E2, we found that one out of two 
Figure 2. Distribution and frequency of mtDNA hypermutation. D-loop–ND1 (nt16331–nt3729, 
NC012920.1), ND1–ATP6 (nt3646–nt9158, NC012920.1), ATP6–ND5 (nt8753–nt12831, NC012920.1), and 
ND5–tRNA-F (nt12540–nt645, NC012920.1) were amplified from two cervical intraepithelial neoplasia 
(CIN) and two oropharyngeal cancer samples along with a plasmid without mutation. The PCR products were 
subjected to next-generation sequencing and the output reads were sorted according to the number of C-to-T 
or G-to-A mutations per read (Tables 1–4). Those with four or more C-to-T/G-to-A mutations were extracted. 
(a) Alignment of reads with four or more C-to-T/G-to-A mutations. The rectangles indicate the positions of the 
extracted reads in the reference sequence of each sample. (b,c) Mutation matrices (b) and dinucleotide analysis 
(c) of the hypermutated reads, obtained from D-loop–ND1 and ND5–tRNA-F, amplified from CIN sample 
#1300. In (c), the contexts of Cs in the reference sequences that corresponded to the mutated Cs in the output 
reads were also analyzed to calculate the expected frequency of each context. The P-values were calculated using 
the chi-square test, comparing the numbers of TpC and non-TpCs, or CpC and non-CpCs. **P < 0.01 and 
***P < 0.005. (d) The consensus sequences obtained from #1300, #2159, KZU33, and KZU45 were aligned with 
revised Cambridge Reference Sequence (NC_012920.1), and the discordant bases were summarized.
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OPCs and one CIN2 contained hypermutation (Supplementary Fig. S4b), as we previously reported28. Although 
it is possible that hypermutation of mtDNA is associated with hypermutation of HPV16 DNA, we were unable to 
draw firm conclusion from the available samples in this study.
Frequency of hypermutated mtDNA. To determine the frequency of hypermutated mtDNA in the 
clinical samples, mtDNA from two CIN (#1300 and #2159) and two OPC samples (KZU33 and KZU45) were 
sequenced by next-generation sequencing (NGS). In practice, the whole mitochondrial genome, covered by four 
PCR amplicons, was amplified by conventional PCR (Supplementary Table), along with a plasmid containing 
D-loop, rRNA, and ND1 genes (nt16331-nt3729, NC_012920.1), to assess the frequency of sequencing errors 
related to NGS procedures, including PCR, library construction, and data analysis. We obtained approximately 
1–2 million reads from each amplicon mapped to the mitochondrial genome (deposited in DRA, accession 
numbers. DRA005375 and DRA005377 for CIN and OPC samples, respectively). Mutations were determined 
by comparison between output reads and a consensus sequence built from each amplicon. The reads were sorted 
according to the number of C-to-T/G-to-A mutations per read (Supplementary Fig. S5). As we previously 
reported28, the number of reads in the plasmid control decreased exponentially with the number of mutations 
per read, and we did not detect any with four or more mutations (Table 1). Thus, most reads with four or more 
mutations are likely to represent hypermutation in vivo, rather than the coincidence of multiple PCR or sequenc-
ing errors.
Of the analyzed samples, #1300, KZU33, and KZU45 but not #2159 contained hypermutated mtDNA, as 
summarized in Tables 1–4 and Fig. 2a. Its frequency was highest in the D-loop–ND1 region of #1300, although it 
was estimated to be as low as 9.66 ppm (=23/2382130, Table 1). Hypermutated reads from the D-loop–ND1 and 
ND5–tRNA-F regions exclusively contained C-to-T/G-to-A mutations, with no other types (Fig. 2b). Both C-to-T 
and G-to-A rich reads appeared to be concentrated on D-loop from #1300 (Figs 2a and S6). Dinucleotide analysis 
further revealed a significant TpC and CpC bias (Fig. 2c), consistent with the proposed signature of A3-mediated 
hypermutation31,32.
Since the mitochondrial genome, especially in the D-loop, was frequently found to be mutated in cervical 
and oral cancers1–5, we built the consensus sequences of the D-loop from the libraries and aligned these with 
the revised Cambridge reference sequence (rCRS, NC_012920.1). We identified mismatched bases, including 
Figure 3. Keratinocyte differentiation induced A3A/B expression and mitochondrial DNA hypermutation. 
W12 cells were differentiated in 1.2 mM CaCl2 for the indicated period of up to 10 days. (a) Nine micrograms 
of total cell lysate were subjected to immunoblotting, to determine the protein levels of A3s, Keratin 10 (K10), 
and GAPDH. (b) RT-qPCR analysis of differentiated W12 cells. Total RNA was harvested and mRNA levels of 
A3s were quantified by RT-qPCR. The copy numbers of A3s were normalized to that of HPRT and indicated as 
fold induction relative to day 0. The mean values and the standard deviations are indicated as bar graphs and 
error bars, respectively. (c) Total DNAs were subjected to 3D-PCR targeting COI, along with plasmid controls 
containing amplicons with 0, 17, and 30 C-to-T mutations. (d,e) The amplicons from a denaturing temperature 
of 85.0 °C or lower were sequenced (d), and the dinucleotide preference of G-to-A mutations are summarized 
(e). The P-values were calculated using unpaired two-tailed Student’s t tests and chi-square tests for the RT-
qPCR analysis and dinucleotide analysis, respectively. *P < 0.05, **P < 0.01, and ***P < 0.005.
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A16464G, A73G, C150T, T204C, A263G, and T489C (Fig. 2d). Of note, C150T has been reportedly associated 
with increased risk of cervical cancer3.
Overall, these data indicate that mtDNA hypermutation occurred in most of regions in mitochondrial genome 
with some biased distribution, albeit at a lower frequency compared to that of HPV16 viral hypermutation28.
A3A, A3B, and mtDNA hypermutation induced by keratinocyte differentiation. To investigate 
the mechanism for mtDNA hypermutation found in CIN and OPC, we made use of a keratinocyte cell line, 
W12 cells, established from CIN1, which differentiates into keratinocytes under a high extracellular calcium 
concentration35,36. By cultivation up to day 10, we confirmed upregulation of an early differentiation marker, K10, 
by western blotting (Fig. 3a). In this experimental condition, the expression of A3s was profiled and the results 
indicated 79.25 and 82.05-fold induction of A3A and A3B at day 10 compared with day 0, respectively (Fig. 3b). 
The levels of other A3s had changed by less than five-fold at day 6 (Fig. 3b). Increased protein levels of A3A and 
A3B were also confirmed by western blotting (Fig. 3a). Total DNA was subjected to 3D-PCR analysis that targeted 
COI. As expected, COI was amplified at a denaturing temperature lower than 85.0 °C (that of the no-mutation 
control, Fig. 3c) by culturing cells in a differentiating condition beyond day 6 (Fig. 3c). Sequencing the amplicons 
revealed an obvious bias of G-to-A over C-to-T mutations, suggesting that A3s target cytosine in the non-coding 
strand of COI gene (Fig. 3d), with a dinucleotide bias toward TpC and CpC (Fig. 3e), as in clinical samples. We 
also found that TP53 was not hypermutated in this condition (Supplementary Fig. S7).
To examine whether differentiation-induced mtDNA hypermutation was dependent on HPV, we also exam-
ined HPV (−)  keratinocytes. Human epidermal keratinocytes immortalized by the ectopic expression of TERT, a 
mutant form of CDK4 and cyclin D1 (HDK-K4DT)37, were induced to differentiate, and A3 profiling and mtDNA 
3D-PCR analysis were performed. The results indicated that A3A (but not A3B) mRNA was upregulated 15-fold 
by 72 h (Supplementary Fig. S8a), and western blotting confirmed an increased protein level of A3A as well as the 
differentiation marker K10 (Supplementary Fig. S8b). It has been reported that A3A consists of two isoforms24; 
the shorter isoform p2 was undetectable in this cell line. Under this condition, the results from COI 3D-PCR 
indicated an increased mutation load in differentiated HDK-K4DT compared to undifferentiated HDK-K4DT 
(Supplementary Fig. S8c). The mutation was biased to non-coding strand, as in W12 (Supplementary Fig. S8d).
For further verification, the differentiation of normal human epidermal keratinocytes (NHEK) was induced; 
the mRNA and protein levels of A3B, and mtDNA hypermutations were found to be increased (Supplementary 
Fig. S8e–g). Taken together, these findings suggest that keratinocyte differentiation induced A3 expression and 
mtDNA hypermutation concurrently in an HPV-independent manner.
Role of A3A/A3B in mtDNA hypermutation. To investigate whether the exogenous expression of A3A or 
A3B (the two major responders among A3s to high-calcium culture in W12 cells) hypermutated mtDNA, these A3s 
were ectopically expressed in W12 cells (Fig. 4a). 3D-PCR analysis targeting COI revealed that A3A and A3B expres-
sion increased the mutation load compared to a control GFP transfectant (Fig. 4b). Sequencing the PCR product 
amplified at a denaturing temperature lower than 84.9 °C (that of the no-mutation control) revealed accumulated 
mutations on the non-coding strand in the A3A and A3B overexpressed W12 cells (Fig. 4c), and the biased dinucle-
otide preference toward TpC (Fig. 4d), as in the CINs, OPCs, and differentiated W12 cells (Figs 1 and 3).
Figure 4. A3A and A3B hypermutated mitochondrial DNA. W12 cells were transfected with expression 
vectors for GFP, A3A, and HA-A3B, and cultivated in maintenance medium for 48 h. (a) The ectopic expression 
of transgenes was validated by western blotting. GAPDH served as a loading control. (b) Total DNAs were 
subjected to 3D-PCR analysis targeting COI. (c,d) PCR products amplified at a denaturing temperature of 
84.5 °C or lower were sequenced (c); the dinucleotide preferences of G-to-A mutations are summarized (d). The 
P-values were calculated by chi-square test. ***P < 0.005.
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To further verify whether endogenous A3A or A3B is involved in mtDNA hypermutation in differentiated 
W12 cells, we transfected siRNA against A3A. Unexpectedly however, siRNA transfection decreased mtDNA 
hypermutation (Supplementary Fig. S9a and b), hampering us from assessing the contribution of endogenous 
A3s. In addition, we lentivirally transduced shRNA against A3A or A3B, and found that mtDNA hypermutation 
load was comparable between shA3A, shA3B, and control shRNA infectants (Supplementary Fig. S9c–e), imply-
ing that induction of either A3A or A3B was sufficient for reducing mtDNA hypermutation.
Since ROS has been demonstrated to regulate keratinocyte differentiation38,39, we attempted to verify its 
involvement in A3A/B induction and mtDNA hypermutation in differentiated W12 cells. To this end, W12 cells 
were induced to differentiate in the presence of a ROS-antagonist, Mito-Q. Results showed that mRNA levels 
of differentiation markers, involucrin and loricrin, were decreased in the presence of 1 μM or 2 μM Mito-Q as 
compared with those of vehicle control (Supplementary Fig. S10). In this condition, A3A was parallelly decreased 
both at the mRNA and protein level. In contrast, the amount of A3B mRNA, but not that of its protein was obvi-
ously affected. Moreover, mtDNA hypermutation was comparable among vehicle and Mito-Q-treated cells. The 
result did not provide evidence that ROS contributed to mtDNA hypermutation.
A3A and A3B are contained in the mitochondrial fraction. To examine whether APOBECs 
could be distributed in mitochondria, nucleus-free lysates from proliferating W12 cells that overexpressed 
A3A or HA-tagged A3B were fractionated into mitochondrial and non-mitochondrial cytosolic fractions. 
Immunoblotting revealed that the mitochondrial fraction contained both A3A and A3B (Fig. 5a). Differentiated 
W12 cells were also fractionated and subjected to immunoblotting; although a fair amount of A3A and A3B 
remained in the nuclear (and unlysed) fraction (Supplementary Fig. S11), as reported in24,40, endogenous 
A3A and A3B were consistently detected in the mitochondrial fractions(Fig. 5b). DNA fragments were sepa-
rately extracted, and subsequent COI 3D-PCR revealed that the mitochondrial fraction contained hypermu-
tated mtDNA (Fig. 5c). Overall, these results suggested that A3A and A3B could potentially be contained in the 
mitochondria.
Discussion
In this study, we demonstrated using 3D-PCR and NGS that cells from CIN and OPC specimens contained hyper-
mutated mtDNA, that correlated with A3B expression (Figs 1 and 2, and Supplementary Figs S1 and S2). Using an 
in vitro experimental system for HPV (+) and (−) keratinocytes, we also demonstrated that differentiation con-
currently induced A3 expression and mtDNA hypermutation (Figs 3 and S8), regardless of HPV. Overexpression 
of A3A and A3B resulted in mtDNA hypermutation (Fig. 4). These results provide evidence of the involvement of 
A3s in differentiation-induced mtDNA mutation.
Cervical tumours have been demonstrated to contain mtDNA mutations, often C-to-T or G-to-A3,13,41. It was 
believed that mtDNA mutations by ROS resulted from DNA oxidization, but we have demonstrated that mtDNA 
contains copies almost entirely without mutations other than C-to-T/G-to-A (Figs 1–4, and Supplementary 
Figs S1 and S8). This can only be explained by A3-mediated hypermutation, rather than by direct DNA oxidation, 
which reportedly generates 8-oxoG resulting in G:C to T:A mutations42.
We compared a standard D-loop sequence with consensus sequences obtained from these specimens and 
identified several mismatches, including C150T, which is reportedly associated with an increased risk of cervical 
cancer (Fig. 2d). Because of the lack of available paired non-tumour samples, we could not determine whether 
they are germline or somatic mutations. Assuming that they are somatic mutations, the result is consistent with 
the reports claiming that CIN contains a mutated D-loop3. We demonstrated that the differentiation of not only 
neoplastic but also normal keratinocytes induces mtDNA hypermutation (Supplementary Fig. S8). Considering 
that normal differentiated keratinocytes exfoliate, while neoplastic cells do not, it is intriguing to speculate that 
neoplastic transformation allows accumulation of mtDNA mutations, which are induced by differentiation.
Figure 5. A3A and A3B were contained in the mitochondria. (a) W12 cells were transfected with an expression 
vector coding A3A or HA-A3B, and cultivated in maintenance medium for 48 h. Their lysates were fractionated 
into cytosolic and mitochondrial fractions, and subjected to western blotting analysis. (b,c) W12 cells were induced 
to differentiate under high extracellular calcium concentration, and fractionated into cytosol and mitochondrial 
fraction, (b) Each fraction was subjected to immunoblotting of A3s, HSP60 (a mitochondrial marker), and 
β-tubulin. (c) DNA was extracted from each fraction and subjected to 3D-PCR analysis targeting COI.
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While the ectopic expression of A3A or A3B was sufficient to induce mtDNA hypermutation (Fig. 4), we could not 
demonstrate the contribution of endogenous A3A or A3B (Supplementary Fig. S9). In addition, Mito-Q treatment did 
not decrease mtDNA hypermutation, when a fair amount of A3B, but not A3A remained to express (Supplementary 
Fig. S10). These results suggest that either A3A or A3B induction is sufficient for mtDNA hypermutation.
While both A3A and A3B were upregulated by differentiation of W12 cells (Fig. 3), either A3A or A3B was 
upregulated in that of HDK-K4DT, or NHEK, respectively (Supplementary Fig. S8). This can be attributed to 
their origin, cervical dysplastic cells for W12 cells, and normal keratinocytes for others. Also, one can speculate 
that A3A/A3B induction in response to differentiation differs individually, explaining the differential induction 
of A3A and A3B in HDK-K4DT and NHEK, respectively. Further studies are warranted to clarify how individual 
difference and/or dysplastic transformation affect A3A/A3B induction by differentiation.
We previously reported that A3A expression level correlates with HPV infection in OPCs20. It was also 
reported that HPV16 E6 and E7 reportedly unregulated A3A and A3B29,30. In contrast, HPV16 infection was not 
obviously associated with mtDNA hypermutation (Supplementary Fig. S2), and the differentiation of HPV (−) 
keratinocytes also hypermutated mtDNA (Supplementary Fig. S8). Nonetheless, overexpression of A3A or A3B 
was sufficient to hypermutate mtDNA (Fig. 4). This discrepancy can be explained as follows; A3 expression deter-
mines mtDNA mutation load, and HPV16 alone cannot induce the expression level of A3s enough for exceeding 
the threshold for mtDNA hypermutation. Besides, we do not deny possible involvement of negative regulators 
associated with HPV16.
mtDNA hypermutation correlated with A3B, but not clearly with A3A (Figs 1d,e and S3). A3A is abundantly 
expressed in hematopoietic cells, especially, macrophages32,43, and as mentioned above, HPV16 E7 induces A3A 
expression30. Thus, we speculate that contamination of blood cells, HPV infection, and other unidentified factors 
may have masked the correlation between A3A and mtDNA hypermutation in vivo. Further studies are warranted 
to verify whether factors other than differentiation affect mtDNA hypermutation.
Suspene et al. demonstrated that ectopic A3A was able to hypermutate mtDNA21. Consistent with this, we 
demonstrated that A3A induction and mtDNA hypermutation occurred concomitantly in differentiating kerat-
inocytes (Figs 3 and S8), and that the ectopic expression of A3A was sufficient to induce mtDNA hypermutation 
in undifferentiated W12 cells (Fig. 4). They claimed that hypermutated mtDNA was confined to the cytosol, based 
on their data that hypermutated mtDNA was vulnerable to treatment with Triton X-100 and DNase I. Indeed, 
we found that the mitochondrial fraction of differentiated W12 cells contained hypermutated mtDNA (Fig. 5c). 
Given that A3A and A3B are contained in the mitochondrial fraction (Fig. 5), and that the cervical cancer mito-
chondrial genome contains substantial C-to-T/G-to-A mutations, we favour the interpretation that A3s can 
enter the mitochondria and mutate mtDNA in situ. Nevertheless, there remains a possibility that hypermutated 
mtDNA is also contained in lysosomes, where damaged mitochondrion are degraded by mitophagy44, and whose 
content will inevitably contaminate the mitochondrial fraction. Further investigation is warranted to verify that 
mtDNA is mutated by APOBECs in situ and inherited by daughter cells.
We found by 3D-PCR targeting COI that hypermutation accumulated on the complementary, but hardly the 
coding strand (Figs 1, 3 and 4, and Supplementary Figs S1 and S8). Also, NGS analysis revealed that the mtDNA 
from specimen #1300 contained significant hypermutation on the D-loop (Figs 2 and S6), which contains the 
replication origin45,46. These findings are consistent with a report by Ju et al.47, that somatic C-to-T substitution 
was biased to the strand from which most mitochondrial genes are transcribed, and that it was exceptionally 
distributed in both strands of D-loop. APOBECs take single-stranded DNA and RNA as their substrates and the 
hypermutation by A3s follows replication and/or transcription48. Thus, these findings may imply that mtDNA 
hypermutation is coupled to replication.
In summary, we have demonstrated that in vivo, mtDNA was hypermutated in CIN, CC, and OPC, and that, 
in vitro, keratinocyte differentiation induced mtDNA hypermutation and A3s expression. mtDNA mutations lead 
to decreased mitochondrial function, and increased levels of ROS8,10. ROS induce mutations, alter the property of 
cancer cells such as growth and metastasis8–10, and promote HPV integration49. We had previously proposed that 
A3s causes the HPV genome to mutate, and promotes its integration20,27,28. Other studies have proposed that A3s 
mutate the chromosomal genome and invoke DNA damage response21,22,50,51. Thus, it is intriguing to speculate 
that A3s and ROS act in synergy to accumulate mutations in the chromosomal, mitochondrial, and HPV genome, 
as well as to promote HPV integration and chromosomal damage (Supplementary Fig. S12). Further studies are 
required to understand the role of A3s, mtDNA hypermutation, and ROS in tumourigenesis.
Materials and Methods
Clinical samples. Cervical swabs and tumour specimens were collected from patients positive for HPV16 
and diagnosed with CIN, CC, or OPC at the Department of Obstetrics and Gynecology or Otorhinolaryngology, 
Kanazawa University Hospital, Japan. The clinical diagnosis was made by histological analysis of punch biopsy sam-
ples obtained under colposcopy for CIN and during surgery for CC and OPC. HPV16 was detected from cervical 
swabs or oropharyngeal specimens as described in28 and20, respectively. For CC specimens, it was determined by 
PCR amplifying HPV16 E6E7, as described in52 (Supplementary Table). Total DNA was isolated using the QIAamp 
DNA Mini Kit (Qiagen, Hilden, Germany) for cervical swabs and OPC surgical specimens, or TaKaRa DEXPAT 
Easy (Kusatsu, Japan) for CC surgical specimens. All the samples were collected after obtaining written informed 
consent from the patients and were used with the approval of the Ethics Committee of Kanazawa University. This 
study was performed in accordance with the World Medical Association’s Declaration of Helsinki.
3D-PCR analysis. Total DNAs were extracted from the cells as described in20,27.For 3D-PCR targeting COI, 
ND2, and TP53, we followed the protocol as described in21, and HPV16 E2 in20,27,28,53. The control plasmids were 
prepared by cloning PCR products containing the indicated number of C-to-T mutations into pGEM-T Easy 
Vector (Promega, Madison, Wisconsin). All of the plasmids used in this study were sequenced at least once for 
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verification. To identify mutations, GenBank accession number NC_012920.1 was used as a reference sequence 
for human mtDNA.
RT-qPCR. The synthesis of cDNA and qPCR were performed as previously reported27,28,54–57. The primers 
used are listed in Supplementary Table. To determine copy numbers of A3s and HPRT1, standard curves were 
generated to quantify the number of transcripts of each gene. For INV and LOR, the delta-delta Ct method was 
adopted, and the results were normalized to HPRT1.
Immunohistochemical analyses. Sections were prepared and stained as described20,58. For staining of 
A3B, the anti-A3B antibody clone ab184990 (1:100, Abcam, Cambridge, UK) was used. Stained sections were 
evaluated by two authors (S.K. and K.W.), who were independently blinded to the clinical data. The number of 
immunoreactive cells and that of total cells were counted in three different visual fields, at a magnification of x400. 
The frequencies of immunoreactive cells were defined as expression scores, and subjected to statistical analysis.
NGS. We followed the strategy as described previously20,28. mtDNA was amplified using four primer pairs59 
(Supplementary Table) that covered the whole mitochondrial genome.
Analysis of the NGS data. The analysis was performed as described previously20,28 and is summarized in 
Supplementary Fig. S5. Reads mapped to the mitochondrial genome were deposited into the DRA database 
(DRA005375 and DRA005377). When considering individual polymorphisms, the consensus sequences were built 
from each library after downsampling, and bases not determined to be single were replaced by N through the use of 
fatt clean (https://github.com/mkasa/klab). To exclude the possibility that any reported haplotypes were misrecog-
nized as hypermutated mtDNA, reads with four or more C-to-T or G-to-A mutations were individually subjected to 
a BLASTN search with the nt dataset, and those more closely matched to reported sequences were excluded.
Cell culture. W12 cells were cultured for maintenance, or induced to differentiate, as described previously in27 
and35,36, respectively. Immortalized keratinocyte was established, maintained, and induced to differentiate as previ-
ously described37. NHEK were purchased from Promo Cell (C-12006, Heidelberg, Germany), and maintained in 
Keratinocyte Growth Medium 2 (D-39006, Heidelberg, Germany). To induce differentiation, NHEK with a passage 
number of less than two were cultivated with 1.2 mM CaCl2 for up to 10 days. siRNA was purchased from Invitrogen 
(siA3A; HSS-153372-74, negative control; 12935-200 and 12935-400). Lipofectamine RNAiMAX (Thermo Fisher, 
13778150) was used for transfection, according to the maker’s protocol. Lentiviral shA3A and shA3B vectors were 
obtained from Sigma (TRCN0000049958 for shA3A, TRCN0000140546 and TRCN0000157469 for shA3B), and 
control shRNA vectors from Addgene (17920 for shSCR60, and 12273 for siGFP61). For preparation of viral super-
natants, the lentiviral vectors were co-transfected with helper vectors, pMD2.G (Addgene12259) and psPAX2 
(Addgene12260), in 293FT cells (Thermo Fisher, R70007), utilizing CalPhos™ Mammalian Transfection Kit 
(Clonetech). The supernatants were applied to W12 cells and selected by puromycin.
Western blotting. Western blotting was performed as previously described20,27,54,58,62. The concentration of 
the lysates was determined by TaKaRa BCA Protein Assay Kit (T9300A), following the manufacture’s protocol. 
A3A and A3B were blotted by either a rabbit serum that reacted to both A3A and A3B20. Other antibodies used in 
this study were as follows: rabbit anti-keratin 10 (K10) (sab4501656, Sigma), rabbit anti-GAPDH (G9545, Sigma), 
horseradish peroxidase (HRP)-conjugated anti-rabbit IgG (GE Healthcare, Little Chalfont, UK), mouse anti-HA 
(Invivogen, San Diego, California), and anti-mouse IgG–HRP (GE Healthcare).
Subcellular fractionation of W12 cells was performed using a Mitochondria Isolation Kit for Cultured Cells 
(Thermo Fisher, 89874) following the manufacturer’s instructions. After the removal of nuclei and unlysed cells, 
supernatants were spun down at 3000 × g for 15 minutes at 4 °C to harvest mitochondria with minimum con-
tamination of lysosomes or peroxisomes. Anti-HSP-60 (GeneTex, Irvine, California, GTX110089) and β-tubulin 
(GeneTex, GTX101279) antibodies were used to validate the purification of the mitochondrial and cytosolic 
fractions, respectively.
Expression vectors and transfection. pmax GFP was obtained from Lonza (Basal, Switzerland), and 
pmax A3A was constructed by inserting an A3A open reading frame (NM_145699) with EcoRI/XhoI ends into 
an AgeI/XhoI arm of pmax GFP. A HA-A3B expression vector was obtained from NIH AIDS Reagent Program 
(Cat# 11090)63. Plasmids were transfected into W12 cells using Fugene 6 (Promega), according to the manufac-
ture’s instruction.
Statistical analysis. Statistical analyses were performed using GraphPad Prism (GraphPad Software, La 
Jolla, California). Two-tailed unpaired t-tests, Pearson’s chi-squared tests, and Mann-Whitney U-tests were used 
for the RT-qPCR analysis, mutation analyses, and IHC, respectively. Differences between experimental groups 
with P values < 0.05 were considered statistically significant. In all the graphs presented for this study, the error 
bars indicate the standard deviation, calculated from duplicated samples63.
References
 1. Chen, D. & Zhan, H. Study on the mutations in the D-loop region of mitochondrial DNA in cervical carcinoma. Journal of cancer 
research and clinical oncology 135, 291–295 (2009).
 2. Sharma, H., Singh, A., Sharma, C., Jain, S. K. & Singh, N. Mutations in the mitochondrial DNA D-loop region are frequent in 
cervical cancer. Cancer cell international 5, 34 (2005).
 3. Zhai, K., Chang, L., Zhang, Q., Liu, B. & Wu, Y. Mitochondrial C150T polymorphism increases the risk of cervical cancer and HPV 
infection. Mitochondrion 11, 559–563 (2011).
www.nature.com/scientificreports/
1 0SCIentIfIC REPORts |  (2018) 8:9745  | DOI:10.1038/s41598-018-27930-z
 4. Lin, J. C., Wang, C. C., Jiang, R. S., Wang, W. Y. & Liu, S. A. Impact of somatic mutations in the D-loop of mitochondrial DNA on the 
survival of oral squamous cell carcinoma patients. Plos one 10, e0124322 (2015).
 5. Prior, S. L. et al. Mitochondrial DNA mutations in oral squamous cell carcinoma. Carcinogenesis 27, 945–950 (2006).
 6. Sabharwal, S. S. & Schumacker, P. T. Mitochondrial ROS in cancer: initiators, amplifiers or an Achilles’ heel? Nat Rev Cancer 14, 
709–721 (2014).
 7. Wallace, D. C. Mitochondria and cancer. Nat Rev Cancer 12, 685–698 (2012).
 8. Ishikawa, K. et al. ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science 320, 661–664 (2008).
 9. Shidara, Y. et al. Positive contribution of pathogenic mutations in the mitochondrial genome to the promotion of cancer by 
prevention from apoptosis. Cancer research 65, 1655–1663 (2005).
 10. Petros, J. A. et al. mtDNA mutations increase tumorigenicity in prostate cancer. Proceedings of the National Academy of Sciences of 
the United States of America 102, 719–724 (2005).
 11. Koshikawa, N., Akimoto, M., Hayashi, J. I., Nagase, H. & Takenaga, K. Association of predicted pathogenic mutations in 
mitochondrial ND genes with distant metastasis in NSCLC and colon cancer. Scientific reports 7, 15535 (2017).
 12. Klaunig, J. E., Kamendulis, L. M. & Hocevar, B. A. Oxidative stress and oxidative damage in carcinogenesis. Toxicologic pathology 38, 
96–109 (2010).
 13. Kabekkodu, S. P. et al. Mitochondrial DNA variation analysis in cervical cancer. Mitochondrion 16, 73–82 (2014).
 14. Goila-Gaur, R. & Strebel, K. HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 5, 51 (2008).
 15. Harris, R. S. & Liddament, M. T. Retroviral restriction by APOBEC proteins. Nat Rev Immunol 4, 868–877 (2004).
 16. Malim, M. H. APOBEC proteins and intrinsic resistance to HIV-1 infection. Philos Trans R Soc Lond B Biol Sci 364, 675–687 (2009).
 17. Vieira, V. C. & Soares, M. A. The role of cytidine deaminases on innate immune responses against human viral infections. BioMed 
research international 2013, 683095 (2013).
 18. Burns, M. B., Temiz, N. A. & Harris, R. S. Evidence for APOBEC3B mutagenesis in multiple human cancers. Nature genetics 45, 
977–983 (2013).
 19. Roberts, S. A. et al. An APOBEC cytidine deaminase mutagenesis pattern is widespread in human cancers. Nature genetics 45, 
970–976 (2013).
 20. Kondo, S. et al. APOBEC3A associates with human papillomavirus genome integration in oropharyngeal cancers. Oncogene 36, 
1687–1697 (2017).
 21. Suspene, R. et al. Somatic hypermutation of human mitochondrial and nuclear DNA by APOBEC3 cytidine deaminases, a pathway 
for DNA catabolism. Proceedings of the National Academy of Sciences of the United States of America 108, 4858–4863 (2011).
 22. Ohba, K. et al. In vivo and in vitro studies suggest a possible involvement of HPV infection in the early stage of breast carcinogenesis 
via APOBEC3B induction. Plos one 9, e97787 (2014).
 23. Landry, S., Narvaiza, I., Linfesty, D. C. & Weitzman, M. D. APOBEC3A can activate the DNA damage response and cause cell-cycle 
arrest. EMBO reports 12, 444–450 (2011).
 24. Mussil, B. et al. Human APOBEC3A isoforms translocate to the nucleus and induce DNA double strand breaks leading to cell stress 
and death. Plos one 8, e73641 (2013).
 25. Fliss, M. S. et al. Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science 287, 2017–2019 (2000).
 26. Chatterjee, A., Mambo, E. & Sidransky, D. Mitochondrial DNA mutations in human cancer. Oncogene 25, 4663–4674 (2006).
 27. Wang, Z. et al. APOBEC3 Deaminases Induce Hypermutation in Human Papillomavirus 16 DNA upon Beta Interferon Stimulation. 
J Virol 88, 1308–1317 (2014).
 28. Wakae, K. et al. Detection of hypermutated human papillomavirus type 16 genome by Next-Generation Sequencing. Virology 485, 
460–466 (2015).
 29. Vieira, V. C. et al. Human papillomavirus E6 triggers upregulation of the antiviral and cancer genomic DNA deaminase APOBEC3B. 
mBio 5 (2014).
 30. Warren, C. J. et al. APOBEC3A functions as a restriction factor of human papillomavirus. J Virol 89, 688–702 (2015).
 31. Henry, M. et al. Genetic editing of HBV DNA by monodomain human APOBEC3 cytidine deaminases and the recombinant nature 
of APOBEC3G. Plos one 4, e4277 (2009).
 32. Stenglein, M. D., Burns, M. B., Li, M., Lengyel, J. & Harris, R. S. APOBEC3 proteins mediate the clearance of foreign DNA from 
human cells. Nature structural & molecular biology 17, 222–229 (2010).
 33. Vartanian, J. P., Guetard, D., Henry, M. & Wain-Hobson, S. Evidence for editing of human papillomavirus DNA by APOBEC3 in 
benign and precancerous lesions. Science 320, 230–233 (2008).
 34. Hultquist, J. F. et al. Human and rhesus APOBEC3D, APOBEC3F, APOBEC3G, and APOBEC3H demonstrate a conserved capacity 
to restrict Vif-deficient HIV-1. J Virol 85, 11220–11234 (2011).
 35. Flores, E. R. & Lambert, P. F. Evidence for a switch in the mode of human papillomavirus type 16 DNA replication during the viral 
life cycle. J Virol 71, 7167–7179 (1997).
 36. Koffa, M. D., Graham, S. V., Takagaki, Y., Manley, J. L. & Clements, J. B. The human papillomavirus type 16 negative regulatory RNA 
element interacts with three proteins that act at different posttranscriptional levels. Proceedings of the National Academy of Sciences 
of the United States of America 97, 4677–4682 (2000).
 37. Egawa, N. et al. The E1 protein of human papillomavirus type 16 is dispensable for maintenance replication of the viral genome. J 
Virol 86, 3276–3283 (2012).
 38. Hamanaka, R. B. et al. Mitochondrial reactive oxygen species promote epidermal differentiation and hair follicle development. 
Science signaling 6, ra8 (2013).
 39. Bause, A. S., Matsui, M. S. & Haigis, M. C. The protein deacetylase SIRT3 prevents oxidative stress-induced keratinocyte 
differentiation. J Biol Chem 288, 36484–36491 (2013).
 40. Lackey, L., Law, E. K., Brown, W. L. & Harris, R. S. Subcellular localization of the APOBEC3 proteins during mitosis and implications 
for genomic DNA deamination. Cell Cycle 12, 762–772 (2013).
 41. Allalunis-Turner, J., Ma, I., Hanson, J. & Pearcey, R. G. mtDNA mutations in invasive cervix tumors: a retrospective analysis. Cancer 
letters 243, 193–201 (2006).
 42. Mazzei, F., Viel, A. & Bignami, M. Role of MUTYH in human cancer. Mutation research 743–744, 33–43 (2013).
 43. Sharma, S. et al. APOBEC3A cytidine deaminase induces RNA editing in monocytes and macrophages. Nature communications 6, 
6881 (2015).
 44. Bingol, B. & Sheng, M. Mechanisms of mitophagy: PINK1, Parkin, USP30 and beyond. Free radical biology & medicine 100, 210–222 
(2016).
 45. Stewart, J. B. & Chinnery, P. F. The dynamics of mitochondrial DNA heteroplasmy: implications for human health and disease. 
Nature reviews. Genetics 16, 530–542 (2015).
 46. Holt, I. J. & Reyes, A. Human mitochondrial DNA replication. Cold Spring Harbor perspectives in biology 4 (2012).
 47. Ju, Y. S. et al. Origins and functional consequences of somatic mitochondrial DNA mutations in human cancer. eLife 3 (2014).
 48. Hoopes, J. I. et al. APOBEC3A and APOBEC3B Preferentially Deaminate the Lagging Strand Template during DNA Replication. 
Cell reports 14, 1273–1282 (2016).
 49. Chen Wongworawat, Y., Filippova, M., Williams, V. M., Filippov, V. & Duerksen-Hughes, P. J. Chronic oxidative stress increases the 
integration frequency of foreign DNA and human papillomavirus 16 in human keratinocytes. American journal of cancer research 6, 
764–780 (2016).
www.nature.com/scientificreports/
1 1SCIentIfIC REPORts |  (2018) 8:9745  | DOI:10.1038/s41598-018-27930-z
 50. Henderson, S., Chakravarthy, A., Su, X., Boshoff, C. & Fenton, T. R. APOBEC-mediated cytosine deamination links PIK3CA helical 
domain mutations to human papillomavirus-driven tumor development. Cell reports 7, 1833–1841 (2014).
 51. Norman, J. M. et al. The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells. 
Nat Immunol 12, 975–983 (2011).
 52. Fujinaga, Y. et al. Simultaneous detection and typing of genital human papillomavirus DNA using the polymerase chain reaction. 
The Journal of general virology 72(Pt 5), 1039–1044 (1991).
 53. Kukimoto, I. et al. Hypermutation in the E2 gene of human papillomavirus type 16 in cervical intraepithelial neoplasia. Journal of 
medical virology 87, 1754–1760 (2015).
 54. Kitamura, K. et al. Uracil DNA glycosylase counteracts APOBEC3G-induced hypermutation of hepatitis B viral genomes: excision 
repair of covalently closed circular DNA. PLoS Pathog 9, e1003361 (2013).
 55. Liang, G. et al. RNA editing of hepatitis B virus transcripts by activation-induced cytidine deaminase. Proceedings of the National 
Academy of Sciences of the United States of America 110, 2246–2251 (2013).
 56. Micallef, L. et al. Effects of extracellular calcium on the growth-differentiation switch in immortalized keratinocyte HaCaT cells 
compared with normal human keratinocytes. Experimental dermatology 18, 143–151 (2009).
 57. Kovacs, D. et al. The eumelanin intermediate 5,6-dihydroxyindole-2-carboxylic acid is a messenger in the cross-talk among 
epidermal cells. The Journal of investigative dermatology 132, 1196–1205 (2012).
 58. Seishima, N. et al. Expression and subcellular localization of AID and APOBEC3 in adenoid and palatine tonsils. Scientific reports 
(in press).
 59. Dames, S. et al. The development of next-generation sequencing assays for the mitochondrial genome and 108 nuclear genes 
associated with mitochondrial disorders. The Journal of molecular diagnostics: JMD 15, 526–534 (2013).
 60. Saharia, A. et al. Flap endonuclease 1 contributes to telomere stability. Current biology: CB 18, 496–500 (2008).
 61. Orimo, A. et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through 
elevated SDF-1/CXCL12 secretion. Cell 121, 335–348 (2005).
 62. Ahasan, M. M. et al. APOBEC3A and 3C decrease human papillomavirus 16 pseudovirion infectivity. Biochemical and biophysical 
research communications 457, 295–299 (2015).
 63. Doehle, B. P., Schafer, A. & Cullen, B. R. Human APOBEC3B is a potent inhibitor of HIV-1 infectivity and is resistant to HIV-1 Vif. 
Virology 339, 281–288 (2005).
Acknowledgements
Computations for NGS analysis were performed on the NIG supercomputer at ROIS National Institute of 
Genetics. The following reagent was obtained through the NIH AIDS Reagent Program, Division of AIDS, 
NIAID, NIH: phAPOBEC3B-HA from Dr. Bryan R. Cullen. pLKO.1 shSCR was a gift from Sheila Stewart 
(Addgene plasmid #17920), pLKO.1 puro GFP siRNA from Bob Weinberg (Addgene plasmid #12273), and 
pMD2.G and psPAX2 from Didier Trono (Addgene plasmid #12259 and #12260). We thank Advanced Preventive 
Medical Sciences Research Center, Kanazawa University for the use of facilities, and Ms. Koura, Ms. Shimadzu, 
Ms. Imayasu, and Ms. Iwauchi for technical support.
Author Contributions
Study conception and design: K.W., M.M.u. Data acquisition: K.W., T.N.i., S.K., L.Q., C.C., K.K.a., K.K.i., M.M.d., 
Z.W., A.M.M., K.H., A.T. Data analysis and interpretation: K.W., T.N.i., S.K., M.M.u. Material supports: S.K., T.I., 
M.N., H.F., T.Y., T.N.a., T.K. Manuscript preparation: K.W., M.M.u.
Additional Information
Supplementary information accompanies this paper at https://doi.org/10.1038/s41598-018-27930-z.
Competing Interests: The authors declare no competing interests.
Publisher's note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and 
institutional affiliations.
Open Access This article is licensed under a Creative Commons Attribution 4.0 International 
License, which permits use, sharing, adaptation, distribution and reproduction in any medium or 
format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Cre-
ative Commons license, and indicate if changes were made. The images or other third party material in this 
article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the 
material. If material is not included in the article’s Creative Commons license and your intended use is not per-
mitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the 
copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.
 
© The Author(s) 2018
